Julie M. Vose, MD

Julie M. Vose, MD, MBA, professor and chief of the Division of Oncology and Hematology; and the George and Peggy Payne Distinguished Chair in Oncology at University of Nebraska Medical Center/Nebraska Medicine

Articles

Dr Vose on the Safety of Epcoritamab in Relapsed/Refractory LBCL

March 12th 2025

Julie M. Vose, MD, MBA, highlights the safety of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Dr Vose on the Investigation of Epcoritamab in Relapsed/Refractory Follicular Lymphoma

June 11th 2024

Julie M. Vose, MD, MBA, discusses the investigation of epcoritamab in relapsed/refractory follicular lymphoma.

Dr Vose on Mitigating Epcoritamab-Associated CRS and Neurologic Toxicities in R/R DLBCL

January 30th 2024

Julie M. Vose, MD, MBA, discusses the mitigation of toxicities with epcoritamab in an optimization cohort of patients with relapsed/refractory DLBCL.

Dr Vose on the SYMPHONY-1 Trial in Relapsed/Refractory Follicular Lymphoma

October 18th 2023

Julie M. Vose, MD, MBA, discusses the investigation of tazemetostat vs placebo when given in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma in the phase 3 SYMPHONY-1 study.

Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

October 4th 2021

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Vose on the Potential Utility of CAR T-Cell Therapy Across Non-Hodgkin Lymphoma

August 20th 2021

Julie M. Vose, MD, MBA, discusses the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma paradigm.

Dr. Vose on Future Research Efforts With CAR T-Cell Therapy in Lymphoma

August 11th 2021

Julie M. Vose, MD, MBA, discusses future research efforts with CAR T-cell therapy in lymphoma.

Dr. Vose on Acalabrutinib/Pembrolizumab Combo in DLBCL

June 19th 2019

Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Dr. Vose Discusses the Importance of Genomic Analysis in NHL

July 18th 2018

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.